SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection

[1]  L. Wall,et al.  SARS-CoV-2 mRNA Vaccines Induce Broad CD4+ T cell Responses that Recognize SARS-CoV-2 Variants and HCoV-NL63 , 2021, Pediatrics.

[2]  J. Blankson,et al.  mRNA Vaccine-Elicited SARS-CoV-2-Specific T cells Persist at 6 Months and Recognize the Delta Variant. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Aaron M. Rosenfeld,et al.  mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern , 2021, Science.

[4]  G. Gao,et al.  One-year sustained cellular and humoral immunities of COVID-19 convalescents , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  A. McDermott,et al.  AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire , 2021, Science Translational Medicine.

[6]  A. Sette,et al.  Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells , 2021, Science.

[7]  E. Wherry,et al.  Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination , 2021, Immunity.

[8]  O. Laeyendecker,et al.  The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Blasczyk,et al.  Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  A. Nowacki,et al.  Necessity of COVID-19 Vaccination in Previously Infected Individuals: A Retrospective Cohort Study , 2021, medRxiv.

[11]  Shibin Zhou,et al.  Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and endemic coronaviruses. , 2021, The Journal of clinical investigation.

[12]  J. Blankson,et al.  SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. , 2021, The Journal of clinical investigation.

[13]  K. Schnatbaum,et al.  Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination , 2021, Science.

[14]  V. Simon,et al.  Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine , 2021, The New England journal of medicine.

[15]  M. Sajadi,et al.  Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. , 2021, JAMA.

[16]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[17]  P. Rosenstiel,et al.  Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19 , 2020, Immunity.

[18]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[19]  H. Rammensee,et al.  SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.

[20]  O. Laeyendecker,et al.  Healthy donor T-cell responses to common cold coronaviruses and SARS-CoV-2. , 2020, The Journal of clinical investigation.

[21]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[22]  U. Reimer,et al.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[23]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[24]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[25]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[26]  P. Sorger,et al.  SARS-CoV-2 infection protects against rechallenge in rhesus macaques , 2020, Science.

[27]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[28]  J. Blankson,et al.  A T Cell Receptor Sequencing-Based Assay Identifies Cross-Reactive Recall CD8+ T Cell Clonotypes Against Autologous HIV-1 Epitope Variants , 2020, Frontiers in Immunology.

[29]  Shuhang Wang,et al.  TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer , 2019, Cancer Immunology Research.

[30]  Ludmila V. Danilova,et al.  Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 , 2019, Journal of Immunotherapy for Cancer.

[31]  Emmanuel Paradis,et al.  ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R , 2018, Bioinform..

[32]  Ludmila V. Danilova,et al.  The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity , 2018, Cancer Immunology Research.

[33]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[34]  S. H. van der Burg,et al.  Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections , 2018, Front. Immunol..

[35]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[36]  Alessandro Sette,et al.  Identifying specificity groups in the T cell receptor repertoire , 2017, Nature.

[37]  Pengpeng Xia,et al.  RNA sensors of the innate immune system and their detection of pathogens , 2017, IUBMB life.

[38]  C. Zahnow,et al.  Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.

[39]  Mingbang Wang,et al.  Analysis of the Repertoire Features of TCR Beta Chain CDR3 in Human by High-Throughput Sequencing , 2016, Cellular Physiology and Biochemistry.

[40]  Mark P. J. van der Loo,et al.  The stringdist Package for Approximate String Matching , 2014, R J..

[41]  Q. Jin,et al.  Limited T Cell Receptor Repertoire Diversity in Tuberculosis Patients Correlates with Clinical Severity , 2012, PloS one.

[42]  B. Autran,et al.  Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. , 2009, Blood.

[43]  David A. Price,et al.  Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover , 2007, The Journal of experimental medicine.

[44]  M. Alexander-Miller.  High-avidity CD8+ T cells , 2005, Immunologic research.